FAPI-P8PN is a fibroblast activation protein (FAP) inhibitor (IC50=3.6 nM). FAPI-P8PN is promising for research of FAP-overexpressing solid tumors.

OZO-H is a GST inhibitor. OZO-H is an OZO derivative with potent anti-cancer effects. OZO-H releases JNK1 from GST-JNK1 complex. OZO-H induces JNK1 phosphorylation and activates c-Jun in cancer cells.

OZO-Cl is an OZO derivative. OZO-Cl has anti-cancer activity. OZO-Cl significantly decreases the intracellular glutathion S-transferase Pi (GST) activity. OZO-Cl exhibits cytotoxicity to cancer cell lines, with IC50s of 150 and 120 μmol/L in Panc-1 and K562 cells respectively.

BO 1341 is a PBPs inhibitor and an antipseudomonal semisynthetic cephalosporin. BO 1341 exhibits antibacterial activity against most Gram-negative bacteria, such as Pseudomonas aeruginosa (MIC90: 1.56 μg/mL), Pseudomonas maltophilia (MIC50: 1.56 μg/mL), and Acinetobacter calcoaceticus (MIC90: 3.13 μg/mL) . BO 1341 can be used in the research of infectious diseases.

DQ 2556 is a semi-synthetic cephalosporin antibiotic. DQ-2556 exhibits significant activity against both Gram-positive and Gram-negative bacteria, particularly Gram-positive bacteria and Enterobacteriaceae infections. DQ 2556 exerts its bactericidal effect by interfering with cell division. DQ-2556 has a strong affinity for the penicillin-binding proteins (PBPs) of Escherichia coli: PBP1A/1B (IC₅₀ = 0.57-0.73 μg/mL) and PBP3 (IC₅₀ = 0.088 μg/mL). DQ-2556 demonstrates significant in vivo protective effects. DQ-2556 can be used in the development of injectable cephalosporins.

ME-1036 (CP-5609) is a carbapenem antibiotic. ME-1036 against resistant Gram-positive organisms, including Methicillin-resistant Staphylococcus aureus (MRSA), and vancomycin-resistant Enterococci (VRE), and ESBL-producing E. coli and K. pneumoniae but is not effective against P. aeruginosa.

Nucresiran is a siRNA that inhibits hepatic synthesis of both wild-type and variant TTR mRNA.

Nucresiran sodium is a siRNA that inhibits hepatic synthesis of both wild-type and variant TTR mRNA.

Nivudirsen is an antisense oligonucleotide that can promote the synthesis of functional dystrophin protein.

Nivudirsen sodium is an antisense oligonucleotide that can promote the synthesis of functional dystrophin protein.

Nelitolimod, a CpG oligonucleotide, is a TLR9 agonist.

Nelitolimod sodium, a CpG oligonucleotide, is a TLR9 agonist.

FBnG-amino-PEG3-C2-azido is a tag-linker conjugate that incorporates a degradation tag FBnG and a glycol linker (Amino-PEG3-C2-Azido). FBnG-amino-PEG3-C2-azido can be used for synthesis of GPX4-AUTAC

Duazomycin (Duazomycin A) sodium is a glutamine antagonist. Duazomycin sodium can significantly enhance the effectiveness of 6-Mercaptopurine (6-MP) in experimental allergic encephalomyelitis (EAE) without increasing toxicity.

Movronersen is an antisense oligonucleotide targeted to α-synuclein.

Movronersen sodium is an antisense oligonucleotide targeted to α-synuclein.

Mivelsiran is a siRNA targeted to amyloid-beta precursor protein (APP). It is used for the study of Alzheimer's disease.

Mivelsiran sodium is a siRNA targeted to amyloid-beta precursor protein (APP). It is used for the study of Alzheimer's disease.

Lufepirsen is an unmodified antisense oligonucleotide targeted to Connexin43 (Cx43). Connexin43 is a specific protein in the eye, which plays a role in wound healing.

Lufepirsen sodium is an unmodified antisense oligonucleotide targeted to Connexin43 (Cx43). Connexin43 is a specific protein in the eye, which plays a role in wound healing.

Lixadesiran is a siRNA in STP705. It targets to COX-2. STP705 is composed of 2 siRNA oligonucleotides (Pixofisiran and Lixadesiran) that individually target TGF-β1 and COX-2 mRNA.

Lixadesiran sodium is a siRNA in STP705. It targets to COX-2. STP705 is composed of 2 siRNA oligonucleotides (Pixofisiran and Lixadesiran) that individually target TGF-β1 and COX-2 mRNA.

Litenimod is potent type B agonist of toll Like receptor 9 (TLR9), triggering both innate and adaptive immune response.

Litenimod sodium is potent type B agonist of toll Like receptor 9 (TLR9), triggering both innate and adaptive immune response.

Lexaptepid Pegol is a pegylated structured L-oligoribonucleotide. It binds and inhibits hepcidin.

Lexaptepid Pegol sodium is a pegylated structured L-oligoribonucleotide. It binds and inhibits hepcidin.

ISIS 1082 is an antisense oligonucleotide targeted to the translation initiation codon of herpes simplex virus (HSV) type 1 and 2 virion capsid protein. It has been shown to inhibit HSV-1 replication in vitro

ISIS 1082 sodium is an antisense oligonucleotide targeted to the translation initiation codon of herpes simplex virus (HSV) type 1 and 2 virion capsid protein. It has been shown to inhibit HSV-1 replication in vitro

IGFIIR aptamer sodium is an IGFIIR-specific aptamer that can be potentially used as a targeting ligand for the treatment and diagnosis of liver fibrosis.

2-Chloro-2′-deoxyadenosine monophosphate is an anticoronavirus agent. It exhibits significant inhibitory effects against wild-type novel coronavirus, novel coronavirus variants (Beta, Delta, and Omicron strains), and other coronaviruses such as human coronavirus 229E, human coronavirus OC43, human coronavirus NL63, and mouse coronavirus MHV.